重庆智翔金泰生物制药股份有限公司关于公司高级管理人员辞职及核心技术人员调整的公告

Core Viewpoint - The company has announced adjustments in its core technical personnel, including the resignation of two key individuals and the addition of a new core technical member, which is not expected to adversely affect its operations or core competencies [2][3][9]. Group 1: Management Changes - Mr. Chang Zhiyuan, the former Deputy General Manager and core technical personnel, has resigned due to personal development and will no longer hold any position within the company [2][3]. - Mr. Shan Jikuan has also been removed from the list of core technical personnel due to work adjustments [2][3]. - The company expresses gratitude for Mr. Chang's contributions during his tenure [3]. Group 2: New Core Technical Personnel - Ms. Zhou Xiaowei has been newly recognized as a core technical personnel member, with a background in genetics and experience in military medical research [8]. - The company emphasizes that the adjustment of core technical personnel will not impact its intellectual property rights or operational capabilities [2][6]. Group 3: Impact of Changes - The company maintains a diverse research and development team with expertise in various fields, ensuring that ongoing projects are not disrupted by the personnel changes [9][10]. - The company has confirmed that all research and development activities are proceeding normally and that the adjustments will not affect its core competitiveness or operational sustainability [9][11]. Group 4: Future Measures - The company plans to continue investing in research and development, enhancing its team structure, and increasing the recruitment and training of personnel to boost innovation capabilities [10].